Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,784 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial.
Kuwabara S, Mori M, Misawa S, Suzuki M, Nishiyama K, Mutoh T, Doi S, Kokubun N, Kamijo M, Yoshikawa H, Abe K, Nishida Y, Okada K, Sekiguchi K, Sakamoto K, Kusunoki S, Sobue G, Kaji R; Glovenin-I CIDP Study Group. Kuwabara S, et al. Among authors: sakamoto k. J Neurol Neurosurg Psychiatry. 2017 Oct;88(10):832-838. doi: 10.1136/jnnp-2017-316427. Epub 2017 Aug 2. J Neurol Neurosurg Psychiatry. 2017. PMID: 28768822 Free PMC article. Clinical Trial.
Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: A multi-center, open-label, 52-week phase 3 trial.
Kuwabara S, Misawa S, Mori M, Iwai Y, Ochi K, Suzuki H, Nodera H, Tamaoka A, Iijima M, Toda T, Yoshikawa H, Kanda T, Sakamoto K, Kusunoki S, Sobue G, Kaji R; Glovenin-I MMN Study Group. Kuwabara S, et al. Among authors: sakamoto k. J Peripher Nerv Syst. 2018 Jun;23(2):115-119. doi: 10.1111/jns.12268. Epub 2018 Apr 24. J Peripher Nerv Syst. 2018. PMID: 29635876 Free PMC article. Clinical Trial.
Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study.
Kanegane H, Endo A, Okada S, Ohnishi H, Ishimura M, Nishikomori R, Imai K, Nonoyama S, Muramatsu H, Wada T, Kuga A, Sakamoto K, Russo-Schwarzbaum S, Chu LH, McCoy B, Li Z, Yel L. Kanegane H, et al. Among authors: sakamoto k. Immunother Adv. 2024 Mar 1;4(1):ltae001. doi: 10.1093/immadv/ltae001. eCollection 2024. Immunother Adv. 2024. PMID: 38511087 Free PMC article.
Simple prediction tools for disease progression in unvaccinated patients with mild/moderate COVID-19 aged under 65 years: Simplified DOATS and DOAT scores.
Shibata Y, Minemura H, Suzuki Y, Nikaido T, Tanino Y, Rikimaru M, Kawamata T, Togawa R, Sato Y, Saito J, Kanazawa K, Iseki K; Doctors in Fukushima and Yamagata against COVID-19. Shibata Y, et al. Respir Investig. 2024 May 22;62(4):681-684. doi: 10.1016/j.resinv.2024.05.006. Online ahead of print. Respir Investig. 2024. PMID: 38781788
Allogeneic Hematopoietic cell Transplantation Using Alemtuzumab in Asian Patients with Inborn Errors of Immunity.
Miyamoto S, Niizato D, Tomomasa D, Nishimura A, Hoshino A, Kamiya T, Isoda T, Takagi M, Kajiwara M, Azumi S, Hirabayashi S, Sakamoto K, Kishimoto K, Miyamura T, Umeda K, Hirose A, Keino D, Yanagimachi M, Kanda K, Sakai Y, Ikawa Y, Watanabe K, Tanaka K, Mori T, Ichinohe T, Sakaguchi H, Morio T, Kanegane H. Miyamoto S, et al. Among authors: sakamoto k. J Clin Immunol. 2024 May 22;44(6):126. doi: 10.1007/s10875-024-01734-5. J Clin Immunol. 2024. PMID: 38773000
On-Surface Synthesis of Polyene-Linked Porphyrin Cooligomer.
Sun K, Ishikawa A, Itaya R, Toichi Y, Yamakado T, Osuka A, Tanaka T, Sakamoto K, Kawai S. Sun K, et al. Among authors: sakamoto k. ACS Nano. 2024 May 28;18(21):13551-13559. doi: 10.1021/acsnano.3c12849. Epub 2024 May 17. ACS Nano. 2024. PMID: 38757371
4,784 results